Candel Therapeutics, Inc. (NASDAQ:CADL – Get Rating) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 51,000 shares, a growth of 38.6% from the November 30th total of 36,800 shares. Based on an average trading volume of 42,600 shares, the days-to-cover ratio is presently 1.2 days. Approximately 0.6% of the shares of the company are short sold.
Candel Therapeutics Stock Up 7.8 %
NASDAQ CADL traded up $0.13 during mid-day trading on Friday, reaching $1.79. 30,919 shares of the stock were exchanged, compared to its average volume of 53,339. The business's 50 day moving average is $1.76 and its 200-day moving average is $2.75. Candel Therapeutics has a 1 year low of $1.40 and a 1 year high of $8.10. The company has a debt-to-equity ratio of 0.40, a quick ratio of 13.41 and a current ratio of 13.41.
Get Candel Therapeutics alerts:Candel Therapeutics (NASDAQ:CADL – Get Rating) last posted its quarterly earnings data on Thursday, November 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.23. The company had revenue of $0.03 million for the quarter. On average, equities analysts forecast that Candel Therapeutics will post -1.28 earnings per share for the current year.
Hedge Funds Weigh In On Candel Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. purchased a new position in Candel Therapeutics during the second quarter valued at $2,408,000. BlackRock Inc. lifted its holdings in Candel Therapeutics by 15.5% during the first quarter. BlackRock Inc. now owns 132,322 shares of the company's stock valued at $674,000 after purchasing an additional 17,708 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new position in Candel Therapeutics during the third quarter valued at $53,000. 21.05% of the stock is owned by hedge funds and other institutional investors.Analyst Upgrades and Downgrades
A number of analysts recently issued reports on CADL shares. Credit Suisse Group lowered their price target on shares of Candel Therapeutics from $10.00 to $8.00 and set an "outperform" rating on the stock in a report on Wednesday, December 7th. HC Wainwright started coverage on shares of Candel Therapeutics in a report on Friday, December 2nd. They set a "buy" rating and a $11.00 price target on the stock.
Candel Therapeutics Company Profile
(Get Rating)
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
See Also
- Get a free copy of the StockNews.com research report on Candel Therapeutics (CADL)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Is Kintara Therapeutics A Hidden Gem?
- Should You Warm up to Generac Stock for the Winter?
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.